Craig Eckfeldt, MD, PhD

• American Cancer Society Mentored Research Scholar 2019-present
• Mpls/St Paul Magazine – Top Doctors Rising Star 2015-2017
• European Hematology Association/American Society of Hematology
• Translational Research Training in Hematology (TRTH) Award 2013
• Alpha Omega Alpha (AOA) Honor Medical Society 2006
• International Society for Experimental Hematology -
• T. Ray Bradley Bradley New Investigator Award 2004

• American Association for Cancer Research 2013-present
• American Society of Hematology 2010-present

Developing novel targeted and immune therapy approaches for acute myeloid leukemia (AML). The goal of the research in our lab is to investigate the genetics and signaling pathways that drive acute myeloid leukemia (AML) to provide a foundation for the development of novel targeted and immune treatment approaches for AML. Our research is focused on identifying the critical pathways that drive AML growth and survival, evaluating the effects of targeted therapies in preclinical cancer models, and studying how targeted therapies influence the susceptibility of cancer cells to immune therapies such as Natural Killer (NK) cell immunotherapy, an area of institutional expertise. We utilize cutting edge molecular genetic techniques and genetically engineered and humanized mouse models including patient-derived AML xenografts for our preclinical studies. Ultimately, we aim to translate our findings to human clinical trials for cancer patients.